KDR and gastric cancer: In 2014, the U.S. Food and Drug Administration (FDA) approved the use of ramucirumab—a monoclonal antibody against vascular endothelial growth factor receptor-2 (VEGFR-2), which was initially used as a monotherapy and subsequently, administered as a combination therapy with paclitaxel—for GC patients.